IL129407A0
(en)
|
1996-10-18 |
2000-02-17 |
Vertex Pharma |
Inhibitors of serine proteases particularly hepatitis C virus NS3 protease pharmaceutical compositions containing the same and the use thereof
|
SV2003000617A
(es)
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
WO2004002999A2
(fr)
|
2002-06-28 |
2004-01-08 |
Idenix (Cayman) Limited |
Promedicaments a nucleosides 2' et 3' destines a traiter les infections aux flavivirus
|
EP1408031A1
(fr)
*
|
2002-10-09 |
2004-04-14 |
3 D Gene Pharma |
Derivés de pyrolidine comme médicaments contre Hepatitis C
|
CA2734052A1
(fr)
|
2003-05-30 |
2005-01-13 |
Pharmasset, Inc. |
Analogues de nucleosides fluores modifies
|
PL1658302T3
(pl)
|
2003-07-25 |
2011-03-31 |
Idenix Pharmaceuticals Inc |
Analogi nukleozydów purynowych do leczenia chorób spowodowanych przez Flaviviridae obejmujących zapalenie wątroby typu C
|
CN1867579A
(zh)
|
2003-08-26 |
2006-11-22 |
先灵公司 |
丙肝病毒的新的肽模拟物ns3-丝氨酸蛋白酶抑制剂
|
MY148123A
(en)
|
2003-09-05 |
2013-02-28 |
Vertex Pharma |
Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
|
KR20060085248A
(ko)
|
2003-09-26 |
2006-07-26 |
쉐링 코포레이션 |
C형 간염 바이러스 ns3 세린 프로테아제의마크로사이클릭 억제제
|
MXPA06005683A
(es)
|
2003-11-20 |
2006-12-14 |
Schering Corp |
Inhibidores despeptidizados de la proteasa ns3 del virus de la hepatitis c.
|
EP1742913A1
(fr)
*
|
2003-12-11 |
2007-01-17 |
Schering Corporation |
Inhibiteurs de la protease serine ns3/ns4a du virus de l'hepatite c (hcv)
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
ATE461209T1
(de)
*
|
2004-01-30 |
2010-04-15 |
Medivir Ab |
Hcv ns-3 serine protease inhibitoren
|
US20050182252A1
(en)
|
2004-02-13 |
2005-08-18 |
Reddy K. R. |
Novel 2'-C-methyl nucleoside derivatives
|
US7816326B2
(en)
|
2004-02-27 |
2010-10-19 |
Schering Corporation |
Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
|
JP2007525510A
(ja)
|
2004-02-27 |
2007-09-06 |
シェーリング コーポレイション |
C型肝炎ウイルスns3セリンプロテアーゼのインヒビターとしての化合物
|
MY145081A
(en)
*
|
2004-02-27 |
2011-12-15 |
Schering Corp |
Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
|
CA2557307A1
(fr)
|
2004-02-27 |
2005-09-22 |
Schering Corporation |
Composes de proline fusionnes a 3,4-(cyclopentyl) en tant qu'inhibiteurs de la protease serine ns3 du virus de l'hepatite c
|
TW200529823A
(en)
|
2004-02-27 |
2005-09-16 |
Schering Corp |
Novel compounds as inhibitors of hepatitis C virus NS3 serine protease
|
TW200536528A
(en)
|
2004-02-27 |
2005-11-16 |
Schering Corp |
Novel inhibitors of hepatitis C virus NS3 protease
|
CN1984922A
(zh)
|
2004-05-20 |
2007-06-20 |
先灵公司 |
用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的取代脯氨酸
|
WO2005123087A2
(fr)
|
2004-06-15 |
2005-12-29 |
Merck & Co., Inc. |
Analogues nucleosidiques de c-purine, servant d'inhibiteurs d'arn-polymerase virale arn-dependante
|
US20070265222A1
(en)
|
2004-06-24 |
2007-11-15 |
Maccoss Malcolm |
Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
|
EP1797111B1
(fr)
|
2004-08-27 |
2011-06-22 |
Schering Corporation |
Composes d'acylsulfonamide inhibiteurs de la serine protease ns3 du virus de l'hepatite c
|
RU2433124C2
(ru)
|
2004-09-14 |
2011-11-10 |
Фармассет, Инк. |
Способ получения 2'-фтор-2'-алкилзамещенных или других замещенных рибофуранозилпиримидинов и пуринов и их производных
|
US7879797B2
(en)
|
2005-05-02 |
2011-02-01 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
WO2006130686A2
(fr)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Administration d'inhibiteurs de protease du vhc en combinaison avec des aliments pour ameliorer la biodisponibilite
|
US20070237818A1
(en)
*
|
2005-06-02 |
2007-10-11 |
Malcolm Bruce A |
Controlled-release formulation of HCV protease inhibitor and methods using the same
|
AU2006252553B2
(en)
*
|
2005-06-02 |
2012-03-29 |
Merck Sharp & Dohme Corp. |
Combination of HCV protease inhibitors with a surfactant
|
JP2008546708A
(ja)
|
2005-06-17 |
2008-12-25 |
ノバルティス アクチエンゲゼルシャフト |
Hcvにおけるサングリフェリンの使用
|
US20110104109A1
(en)
*
|
2005-07-13 |
2011-05-05 |
Frank Bennett |
Tetracyclic indole derivatives and their use for treating or preventing viral infections
|
US7470664B2
(en)
|
2005-07-20 |
2008-12-30 |
Merck & Co., Inc. |
HCV NS3 protease inhibitors
|
WO2007016441A1
(fr)
|
2005-08-01 |
2007-02-08 |
Merck & Co., Inc. |
Peptides macrocycliques en tant qu’inhibiteurs de la protéase ns3 du vhc
|
US7632821B2
(en)
|
2005-08-09 |
2009-12-15 |
Merck & Co., Inc. |
Ribonucleoside cyclic acetal derivatives for the treatment of RNA-dependent RNA viral infection
|
US7964624B1
(en)
|
2005-08-26 |
2011-06-21 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
AR055395A1
(es)
*
|
2005-08-26 |
2007-08-22 |
Vertex Pharma |
Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
|
US7705138B2
(en)
|
2005-11-11 |
2010-04-27 |
Vertex Pharmaceuticals Incorporated |
Hepatitis C virus variants
|
EP2392589A3
(fr)
|
2005-11-11 |
2012-06-20 |
Vertex Pharmaceuticals Incorporated |
Variantes du virus de l'hépatite C
|
US7816348B2
(en)
|
2006-02-03 |
2010-10-19 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
AU2007217355B2
(en)
|
2006-02-27 |
2012-06-21 |
Vertex Pharmaceuticals Incorporated |
Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same
|
CA2646229A1
(fr)
|
2006-03-16 |
2007-09-27 |
Vertex Pharmaceuticals Incorporated |
Inhibiteurs de protease de l'hepatite c deuteres
|
WO2007111866A2
(fr)
*
|
2006-03-23 |
2007-10-04 |
Schering Corporation |
Combinaisons d'un ou plusieurs inhibiteurs de la protéase du vhc et d'un ou plusieurs inhibiteurs de cyp3a4, et méthodes de traitement associées
|
CA2643680A1
(fr)
|
2006-04-11 |
2007-11-22 |
Novartis Ag |
Composes organiques et leurs utilisations
|
GB0609492D0
(en)
|
2006-05-15 |
2006-06-21 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
CA2653662C
(fr)
*
|
2006-06-01 |
2015-02-10 |
Sanofi-Aventis |
Nitriles spirocycliques en tant qu'inhibiteurs de protease
|
GB0612423D0
(en)
|
2006-06-23 |
2006-08-02 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
RU2009109355A
(ru)
|
2006-08-17 |
2010-09-27 |
БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) |
Ингибиторы вырусной полимеразы
|
EP2076278B1
(fr)
|
2006-10-24 |
2015-05-06 |
Merck Sharp & Dohme Corp. |
Inhibiteurs macrocycliques de la protéase HCV NS3
|
EP2079479B1
(fr)
|
2006-10-24 |
2014-11-26 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de la protéase ns3 du vhc
|
EP2079480B1
(fr)
|
2006-10-24 |
2013-06-05 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de la protéase ns3 du hcv
|
CN101568346B
(zh)
|
2006-10-27 |
2015-11-25 |
默沙东公司 |
Hcv ns3蛋白酶抑制剂
|
MX2009004556A
(es)
|
2006-10-27 |
2009-07-10 |
Merck & Co Inc |
Inhibidores de la proteasa ns3 del hcv.
|
GB0625349D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
CN103224506A
(zh)
|
2006-12-20 |
2013-07-31 |
P.安杰莱蒂分子生物学研究所 |
抗病毒的吲哚
|
GB0625345D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
EP2081922B1
(fr)
|
2006-12-22 |
2012-02-01 |
Schering Corporation |
Dérivés indoliques condensés en 5,6 à un cycle et leur utilisation
|
AU2007339382B2
(en)
|
2006-12-22 |
2013-05-02 |
Merck Sharp & Dohme Llc |
4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
|
KR20090106539A
(ko)
*
|
2006-12-22 |
2009-10-09 |
쉐링 코포레이션 |
Hcv 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체
|
TW200846343A
(en)
*
|
2007-02-27 |
2008-12-01 |
Vertex Pharma |
Co-crystals and pharmaceutical compositions comprising the same
|
WO2008106058A2
(fr)
|
2007-02-27 |
2008-09-04 |
Vertex Pharmaceuticals Incorporated |
Inhibiteurs de sérine protéases
|
WO2008106167A1
(fr)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Polythérapie incluant des inhibiteurs de métalloprotéinases matricielles et des inhibiteurs de caspases pour le traitement de maladies hépatiques
|
PT2144604E
(pt)
|
2007-02-28 |
2011-10-19 |
Conatus Pharmaceuticals Inc |
Métodos para o tratamento da hepatite c viral crónica utilizando ro-113-0830
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
AU2008277440A1
(en)
|
2007-07-17 |
2009-01-22 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Macrocyclic indole derivatives for the treatment of hepatitis C infections
|
US8927569B2
(en)
|
2007-07-19 |
2015-01-06 |
Merck Sharp & Dohme Corp. |
Macrocyclic compounds as antiviral agents
|
US8242140B2
(en)
|
2007-08-03 |
2012-08-14 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
MX2010002317A
(es)
*
|
2007-08-29 |
2010-03-22 |
Schering Corp |
Derivados de indol sustituidos y metodos para su utilizacion.
|
AU2008295476B2
(en)
*
|
2007-08-29 |
2013-08-01 |
Merck Sharp & Dohme Corp. |
2, 3-Substituted Indole Derivatives for treating viral infections
|
EP2195317B1
(fr)
|
2007-08-29 |
2012-01-18 |
Schering Corporation |
Dérivés d'azaindoles substitués en 2 et 3 destinés au traitement d'infections virales
|
ATE530546T1
(de)
|
2007-08-30 |
2011-11-15 |
Vertex Pharma |
Kokristalle und pharmazeutische zusammensetzungen damit
|
US8383583B2
(en)
|
2007-10-26 |
2013-02-26 |
Enanta Pharmaceuticals, Inc. |
Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
|
MX2010005261A
(es)
|
2007-11-14 |
2010-10-15 |
Enanta Pharm Inc |
Inhibidores macrocíclicos de proteasa de serina de hepatitis c de tetrazolilo.
|
CN102099351A
(zh)
*
|
2007-11-16 |
2011-06-15 |
先灵公司 |
3-杂环取代的吲哚衍生物及其使用方法
|
WO2009064852A1
(fr)
*
|
2007-11-16 |
2009-05-22 |
Schering Corporation |
Dérivés d'indole à substitution par aminosulfonyle en position 3 et leurs procédés d'utilisation
|
WO2009079353A1
(fr)
|
2007-12-14 |
2009-06-25 |
Enanta Pharmaceuticals, Inc. |
Inhibiteurs macrocycliques contenant du triazole des protéases à sérine du vhc
|
JP5623289B2
(ja)
|
2007-12-19 |
2014-11-12 |
ベーリンガーインゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ウイルスポリメラーゼインヒビター
|
MX2010008523A
(es)
|
2008-02-04 |
2010-08-31 |
Idenix Pharmaceuticals Inc |
Inhibidores macrociclicos de serina proteasa.
|
JP5490778B2
(ja)
|
2008-03-20 |
2014-05-14 |
エナンタ ファーマシューティカルズ インコーポレイテッド |
C型肝炎ウイルス阻害剤としてのフッ素化大環状化合物
|
TW200946541A
(en)
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
US8461107B2
(en)
|
2008-04-28 |
2013-06-11 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
JP5580814B2
(ja)
*
|
2008-06-13 |
2014-08-27 |
メルク・シャープ・アンド・ドーム・コーポレーション |
3環式インドール誘導体およびその使用方法
|
BRPI0913677A2
(pt)
|
2008-07-02 |
2015-12-15 |
Idenix Pharmaceuticals Inc |
composto, metabólito purificado, método para tratar um hospedeiro infectado com um vírus flaviviridade, composição farmacêutica, método para preparar o composto purificado, e, processo para preparar o composto
|
SI2310095T1
(sl)
|
2008-07-22 |
2013-01-31 |
Merck Sharp & Dohme Corp. |
Makrocikliäśne kuinoksalinske spojine kot hcv ns3 proteazni inhibitorji
|
US8470834B2
(en)
|
2008-08-20 |
2013-06-25 |
Merck Sharp & Dohme Corp. |
AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
TW201020245A
(en)
|
2008-08-20 |
2010-06-01 |
Schering Corp |
Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
AU2009282574B2
(en)
|
2008-08-20 |
2014-08-21 |
Merck Sharp & Dohme Corp. |
Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
AU2009282567B2
(en)
|
2008-08-20 |
2014-10-02 |
Merck Sharp & Dohme Corp. |
Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
US8044087B2
(en)
*
|
2008-09-29 |
2011-10-25 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CL2009002206A1
(es)
|
2008-12-23 |
2011-08-26 |
Gilead Pharmasset Llc |
Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
|
NZ593648A
(en)
|
2008-12-23 |
2013-09-27 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
EA201100851A1
(ru)
|
2008-12-23 |
2012-04-30 |
Фармассет, Инк. |
Аналоги нуклеозидов
|
AU2010203656A1
(en)
|
2009-01-07 |
2011-07-21 |
Scynexis, Inc. |
Cyclosporine derivative for use in the treatment of HCV and HIV infection
|
WO2010082050A1
(fr)
|
2009-01-16 |
2010-07-22 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Composés benzoxazocines substitués 7-aminoalkyle macrocycycliques destinés au traitement des infections par hépatite c
|
GB0900914D0
(en)
|
2009-01-20 |
2009-03-04 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
US8102720B2
(en)
*
|
2009-02-02 |
2012-01-24 |
Qualcomm Incorporated |
System and method of pulse generation
|
JP5690286B2
(ja)
|
2009-03-04 |
2015-03-25 |
イデニク プハルマセウティカルス,インコーポレイテッド |
ホスホチオフェン及びホスホチアゾールhcvポリメラーゼ阻害剤
|
WO2010118078A1
(fr)
|
2009-04-08 |
2010-10-14 |
Idenix Pharmaceuticals, Inc. |
Inhibiteurs macrocycliques de la sérine protéase
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
TWI576352B
(zh)
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
AU2010253791A1
(en)
|
2009-05-29 |
2011-11-24 |
Merck Sharp & Dohme Corp. |
Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C
|
CN101605432B
(zh)
*
|
2009-07-10 |
2011-08-24 |
番禺南沙殷田化工有限公司 |
刚性印刷电路板的自动湿法贴膜方法
|
EP2459582B1
(fr)
|
2009-07-30 |
2015-05-27 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de protéase ns3 du virus de l'hépatite c
|
WO2011017389A1
(fr)
|
2009-08-05 |
2011-02-10 |
Idenix Pharmaceuticals, Inc. |
Inhibiteurs macrocycliques de la sérine protéase macrocyclique utiles contre les infections virales, en particulier le virus de lhépatite c
|
WO2011063076A1
(fr)
|
2009-11-19 |
2011-05-26 |
Itherx Pharmaceuticals, Inc. |
Méthodes de traitement du virus de l'hépatite c avec des composés d'oxo-acétamide
|
AU2010324871A1
(en)
|
2009-11-25 |
2012-06-14 |
Merck Sharp & Dohme Corp. |
Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
|
MY159958A
(en)
|
2009-12-18 |
2017-02-15 |
Idenix Pharmaceuticals Inc |
5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
|
AU2010341537A1
(en)
|
2009-12-22 |
2012-08-09 |
Merck Sharp & Dohme Corp. |
Fused Tricyclic Compounds and methods of use thereof for the treatment of viral diseases
|
US9433621B2
(en)
|
2010-02-18 |
2016-09-06 |
Merck Sharp & Dohme Corp. |
Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
SG183526A1
(en)
|
2010-03-09 |
2012-09-27 |
Merck Sharp & Dohme |
Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
|
BR112012024884A2
(pt)
|
2010-03-31 |
2016-10-18 |
Gilead Pharmasset Llc |
síntese estereosseletiva de ativos contendo fósforo
|
MX2012011222A
(es)
|
2010-04-01 |
2013-01-18 |
Centre Nat Rech Scient |
Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales.
|
JP2013541499A
(ja)
|
2010-07-26 |
2013-11-14 |
メルク・シャープ・エンド・ドーム・コーポレイション |
置換されたビフェニレン化合物およびウイルス性疾患の治療のためのその使用方法
|
AU2011314168A1
(en)
|
2010-09-29 |
2013-04-04 |
Merck Sharp & Dohme Corp. |
Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
|
US9011833B2
(en)
|
2010-10-08 |
2015-04-21 |
Novartis Ag |
Vitamin E formulations of sulfamide NS3 inhibitors
|
AR084044A1
(es)
|
2010-11-30 |
2013-04-17 |
Pharmasset Inc |
Compuestos 2’-espiro-nucleosidos
|
US9353100B2
(en)
|
2011-02-10 |
2016-05-31 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
WO2012154321A1
(fr)
|
2011-03-31 |
2012-11-15 |
Idenix Pharmaceuticals, Inc. |
Composés et compositions pharmaceutiques pour le traitement d'infections virales
|
BR112013026345A2
(pt)
|
2011-04-13 |
2019-04-24 |
Merck Sharp & Dohe Corp. |
composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
|
US9156872B2
(en)
|
2011-04-13 |
2015-10-13 |
Merck Sharp & Dohme Corp. |
2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
WO2013033900A1
(fr)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de maladies virales
|
WO2013033901A1
(fr)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Dérivés benzofuranes substitués par un hétérocycle et leurs procédés d'utilisation pour le traitement de maladies virales
|
WO2013033899A1
(fr)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Composés benzofuranes substitués et leur procédés d'utilisation pour le traitement de maladies virales
|
AU2012308900A1
(en)
|
2011-09-12 |
2013-05-09 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
WO2013039920A1
(fr)
|
2011-09-12 |
2013-03-21 |
Idenix Pharmaceuticals, Inc. |
Composés de carbonyloxyméthylphosphoramidate substitué et compositions pharmaceutiques servant à traiter les infections virales
|
EP2755981A4
(fr)
|
2011-09-14 |
2015-03-25 |
Merck Sharp & Dohme |
Composés hétérocycliques contenant un silyle et méthodes d'utilisation desdits composés pour traiter les maladies virales
|
EP2768838A1
(fr)
|
2011-10-14 |
2014-08-27 |
IDENIX Pharmaceuticals, Inc. |
Phosphates 3',5'-cycliques substitués de composés nucléotidiques purines et compositions pharmaceutiques pour le traitement d'infections virales
|
EP2780026B1
(fr)
|
2011-11-15 |
2019-10-23 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de la protéase ns3 du vhc
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
US9089574B2
(en)
|
2011-11-30 |
2015-07-28 |
Emory University |
Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
|
US20140356325A1
(en)
|
2012-01-12 |
2014-12-04 |
Ligand Pharmaceuticals Incorporated |
Novel 2'-c-methyl nucleoside derivative compounds
|
US20130217644A1
(en)
|
2012-02-13 |
2013-08-22 |
Idenix Pharmaceuticals, Inc. |
Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate]
|
EP2852605B1
(fr)
|
2012-05-22 |
2018-01-31 |
Idenix Pharmaceuticals LLC |
Promédicaments de 3',5'-phosphate cyclique pour traiter une infection par le virus de l'hépatite c
|
WO2013177188A1
(fr)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
Promédicaments de 3',5'-phosphoramidate cyclique pour traiter une infection par le virus de l'hépatite c
|
AP3913A
(en)
|
2012-05-22 |
2016-11-26 |
Idenix Pharamaceuticals Inc |
D-amino acid compounds for liver disease
|
UA119315C2
(uk)
|
2012-07-03 |
2019-06-10 |
Гіліад Фармассет Елелсі |
Інгібітори вірусу гепатиту с
|
PE20151318A1
(es)
|
2012-10-08 |
2015-10-03 |
Idenix Pharmaceuticals Inc |
Analogos de 2'-cloro nucleosido para infeccion por vhc
|
WO2014063019A1
(fr)
|
2012-10-19 |
2014-04-24 |
Idenix Pharmaceuticals, Inc. |
Composés dinucléotides contre une infection par le vhc
|
US10723754B2
(en)
|
2012-10-22 |
2020-07-28 |
Idenix Pharmaceuticals Llc |
2′,4′-bridged nucleosides for HCV infection
|
WO2014078436A1
(fr)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
Ester de d-alanine d'analogue de sp-nucléoside
|
US20140140951A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Rp-Nucleoside Analog
|
EP2935304A1
(fr)
|
2012-12-19 |
2015-10-28 |
IDENIX Pharmaceuticals, Inc. |
4'-fluoro-nucléosides pour le traitement du vhc
|
WO2014121418A1
(fr)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Composés hétérocycliques tétracycliques et leurs méthodes d'utilisation pour le traitement de l'hépatite c
|
WO2014121417A1
(fr)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de l'hépatite c
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
WO2014137926A1
(fr)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
3'-désoxynucléosides utilisables en vue du traitement d'une infection par le vhc
|
CN105073758B
(zh)
|
2013-03-15 |
2017-08-11 |
吉利德科学公司 |
丙型肝炎病毒抑制剂
|
US9187515B2
(en)
|
2013-04-01 |
2015-11-17 |
Idenix Pharmaceuticals Llc |
2′,4′-fluoro nucleosides for the treatment of HCV
|
EP3004130B1
(fr)
|
2013-06-05 |
2019-08-07 |
Idenix Pharmaceuticals LLC. |
1',4'-thio nucléosides pour le traitement du virus de l'hépatite c (vhc)
|
WO2015017713A1
(fr)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
Pronucléotides phosphoramidates avec acides aminés d de composés halogéno pyrimidines pour le traitement des hépatopathies
|
ES2792503T3
(es)
|
2013-08-27 |
2020-11-11 |
Gilead Pharmasset Llc |
Formulación combinada de dos compuestos antivirales
|
EP3046924A1
(fr)
|
2013-09-20 |
2016-07-27 |
IDENIX Pharmaceuticals, Inc. |
Inhibiteurs du virus de l'hépatite c
|
WO2015061683A1
(fr)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
Pronucléotides thiophosphoramidates à acide aminé d et pronucléotides thiophosphoramidates à d-analine de composés de nucléoside utiles pour le traitement du vhc
|
WO2015065817A1
(fr)
|
2013-10-30 |
2015-05-07 |
Merck Sharp & Dohme Corp. |
Pseudopolymorphes d'un inhibiteur de la protéine ns5a du vhc et leurs utilisations
|
EP3063165A1
(fr)
|
2013-11-01 |
2016-09-07 |
Idenix Pharmaceuticals LLC |
Pronucléotides phosphoramidates de d-alanine de composés de nucléoside 2'-méthyl 2'-fluoro guanosine dans le traitement du vhc
|
US20170198005A1
(en)
|
2013-11-27 |
2017-07-13 |
Idenix Pharmaceuticals Llc |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
EP3083654A1
(fr)
|
2013-12-18 |
2016-10-26 |
Idenix Pharmaceuticals LLC |
Nucléosides 4'-or pour le traitement du vhc
|
US10449210B2
(en)
|
2014-02-13 |
2019-10-22 |
Ligand Pharmaceuticals Inc. |
Prodrug compounds and their uses
|
US20170135990A1
(en)
|
2014-03-05 |
2017-05-18 |
Idenix Pharmaceuticals Llc |
Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
|
US20170066795A1
(en)
|
2014-03-05 |
2017-03-09 |
Idenix Pharmaceuticals Llc |
Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv
|
US20170066779A1
(en)
|
2014-03-05 |
2017-03-09 |
Idenix Pharmaceuticals Llc |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
EP3131914B1
(fr)
|
2014-04-16 |
2023-05-10 |
Idenix Pharmaceuticals LLC |
Nucléosides méthyle ou alcynyle substitués en position 3 pour le traitement du virus de l'hépatite c
|
CN106687118A
(zh)
|
2014-07-02 |
2017-05-17 |
配体药物公司 |
前药化合物及其用途
|
CN105153005A
(zh)
*
|
2015-08-05 |
2015-12-16 |
上海瑞博化学有限公司 |
一种4-羰基-脯氨酸衍生物的制备方法
|
EP3512836A1
(fr)
*
|
2016-09-13 |
2019-07-24 |
Haplogen GmbH |
Composés antiviraux
|
US11970482B2
(en)
|
2018-01-09 |
2024-04-30 |
Ligand Pharmaceuticals Inc. |
Acetal compounds and therapeutic uses thereof
|